CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, contiguous announced that it volition big a unrecorded webinar on, Tuesday, December 6, astatine 8:00 a.m. ET to contiguous archetypal objective information from the Phase 1/2 RUBY proceedings of EDIT-301, nether improvement for the attraction of terrible sickle compartment disease. The objective information volition see information information from the archetypal 2 patients and efficacy information from the archetypal diligent treated with EDIT-301.
The unrecorded and archived webcast of the presumption volition beryllium accessible done this webcast link, oregon done the Events & Presentations leafage of the “Investors” conception of the Company’s website. The presumption volition besides beryllium disposable for download soon aft the webinar.
A replay of the webinar and webinar materials volition beryllium disposable upon decision of the webinar successful the Investors conception of the Editas Medicine website at https://www.editasmedicine.com/.
About Sickle Cell Disease
Sickle compartment illness is an inherited humor upset caused by a mutation successful the beta-globin cistron that leads to polymerization of the sickle hemoglobin macromolecule (HbS). In sickle compartment disease, the reddish humor cells are misshapen successful a sickle signifier alternatively of a emblematic disc shape. The abnormal signifier causes the reddish humor cells to person shortened lifespan and to artifact humor travel causing anemia, symptom crises, organ failure, and aboriginal death. There are an estimated 100,000 radical successful the United States presently surviving with sickle compartment disease. Higher levels of fetal hemoglobin (HbF) inhibit HbS polymerization, frankincense reducing the manifestation of sickling.
About EDIT-301
EDIT-301 is an experimental compartment therapy medicine nether probe for the attraction of terrible sickle compartment illness (SCD) and transfusion-dependent beta thalassemia (TDT). EDIT-301 consists of patient-derived CD34+ hematopoietic stem and progenitor cells edited astatine the gamma globin cistron (HBG1 and HBG2) promoters, wherever people occurring fetal hemoglobin (HbF) inducing mutations reside, by a highly circumstantial and businesslike proprietary engineered AsCas12a nuclease. Red humor cells derived from EDIT-301 CD34+ cells show a sustained summation successful fetal hemoglobin production, which has the imaginable to supply a one-time, durable attraction payment for radical surviving with terrible SCD and TDT.
About RUBY
The RUBY proceedings is simply a single-arm, open-label, multi-center Phase 1/2 survey designed to measure the information and efficacy of EDIT-301 successful patients with terrible sickle compartment disease. Enrolled patients volition person a azygous medication of EDIT-301. Additional details are disposable on www.clinicaltrials.gov (NCT#04853576).
About Editas Medicine
As a objective signifier genome editing company, Editas Medicine is focused connected translating the powerfulness and imaginable of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for radical surviving with superior diseases astir the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a wide people of diseases. Editas Medicine is the exclusive licensee of Broad Institute and Harvard University’s Cas9 patent estates and Broad Institute’s Cas12a patent property for quality medicines. For the latest accusation and technological presentations, delight sojourn www.editasmedicine.com.
English (US)